Compare · AVTX vs JNJ
AVTX vs JNJ
Side-by-side comparison of Avalo Therapeutics Inc. (AVTX) and Johnson & Johnson (JNJ): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both AVTX and JNJ operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- JNJ is the larger of the two at $538.04B, about 649.9x AVTX ($827.9M).
- Over the past year, AVTX is up 255.0% and JNJ is up 43.8% - AVTX leads by 211.1 points.
- AVTX has been more active in the news (16 items in the past 4 weeks vs 11 for JNJ).
- JNJ has more recent analyst coverage (25 ratings vs 18 for AVTX).
- Company
- Avalo Therapeutics Inc.
- Johnson & Johnson
- Price
- $15.76-1.07%
- $223.50-0.77%
- Market cap
- $827.9M
- $538.04B
- 1M return
- +17.52%
- -2.80%
- 1Y return
- +254.95%
- +43.82%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2015
- News (4w)
- 16
- 11
- Recent ratings
- 18
- 25
Johnson & Johnson
Johnson & Johnson researches and develops, manufactures, and sells a range of products in the health care field worldwide. It operates through three segments: Consumer Health, Pharmaceutical, and Medical Devices. The Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; smoking cessation products under the NICORETTE brand; and acid reflux products under the PEPCID brand. This segment also provides women's health products, such as sanitary pads and tampons under the STAYFREE, CAREFREE, and o.b. brands; wound care products comprising adhesive bandages under the BAND-AID brand; and first aid products under the NEOSPORIN brand. The Pharmaceutical segment offers products in various therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, pulmonary hypertension, and cardiovascular and metabolic diseases. The Medical Devices segment provides electrophysiology products to treat cardiovascular diseases and neurovascular care products to treat hemorrhagic and ischemic stroke; orthopaedics products in support of hips, knees, trauma, spine, sports, and other; advanced and general surgery solutions that focus on breast aesthetics, ear, nose, and throat procedures; and disposable contact lenses and ophthalmic products related to cataract and laser refractive surgery under the ACUVUE brand. The company markets its products to general public, and retail outlets and distributors, as well as distributes directly to wholesalers, hospitals, and health care professionals for prescription use. Johnson & Johnson was founded in 1886 and is based in New Brunswick, New Jersey.
Latest AVTX
- Chief Medical Officer Doyle Mittie exercised 679 shares at a strike of $8.04 and sold $10,864 worth of shares (679 units at $16.00) as part of a pre-agreed trading plan (SEC Form 4)
- Chief Executive Officer Neil Garry Arthur was granted 100,200 shares, increasing direct ownership by 111% to 190,314 units (SEC Form 4)
- Chief Legal Officer Varki Paul was granted 24,300 shares, increasing direct ownership by 669% to 27,934 units (SEC Form 4)
- Chief Medical Officer Doyle Mittie was granted 43,500 shares, increasing direct ownership by 1,201% to 47,122 units (SEC Form 4)
- Chief Financial Officer Sullivan Christopher Ryan was granted 39,900 shares, increasing direct ownership by 9,433% to 40,323 units (SEC Form 4)
- Chief Strategy Officer Riley Jennifer was granted 34,200 shares, increasing direct ownership by 1,288% to 36,855 units (SEC Form 4)
- Avalo Therapeutics Announces Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)
- Chief Medical Officer Doyle Mittie sold $56,280 worth of shares (3,000 units at $18.76) as part of a pre-agreed trading plan and exercised 3,000 shares at a strike of $12.65 (SEC Form 4)
- Amendment: SEC Form SCHEDULE 13G/A filed by Avalo Therapeutics Inc.
- Amendment: SEC Form SCHEDULE 13G/A filed by Avalo Therapeutics Inc.
Latest JNJ
- Johnson & Johnson's Phase 3 prostate cancer study shows ERLEADA® (apalutamide) before and after surgery significantly reduces risk of metastasis or death, breaking a decades-long treatment paradigm
- RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE® (lazertinib) demonstrates prolonged clinical benefit as a first-line treatment for atypical EGFR-mutated non-small cell lung cancer
- New TECVAYLI® (teclistamab-cqyv) data demonstrate superior progression-free and overall survival as early as first relapse in multiple myeloma
- FDA approves label expansion, cementing TREMFYA® as the only IL‑23 inhibitor proven to help stop further joint damage
- Johnson & Johnson to Host Investor Conference Call on Second-Quarter Results
- SEC Form SD filed by Johnson & Johnson
- SEC Form 13F-HR filed by Johnson & Johnson
- CNS Drug Delivery Technologies Are Reshaping Alzheimer's and Biodefense Research
- Johnson & Johnson upgraded by Leerink Partners with a new price target
- Johnson & Johnson to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference